Nyssa Noyola - Ascendis Pharma Vice Management
Executive
Nyssa Noyola is Vice Management of Ascendis Pharma AS
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1738) % which means that it has lost $0.1738 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.76, whereas Return On Tangible Assets are forecasted to decline to (0.34). At present, Ascendis Pharma's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 1.1 B, whereas Other Current Assets are forecasted to decline to about 16.2 M.Ascendis Pharma AS currently holds 856.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Ascendis Pharma AS has a current ratio of 9.47, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ascendis Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Jason Hoitt | Stoke Therapeutics | 47 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Kevin Gray | United Therapeutics | N/A | |
| Adam Townsend | Apellis Pharmaceuticals | 47 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Lauren MBA | Day One Biopharmaceuticals | 49 | |
| Patrick Lamy | Akero Therapeutics | 52 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Thomas Ross | Akero Therapeutics | N/A | |
| Andrew Schwendenman | Replimune Group | 49 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Holly Hobson | United Therapeutics | N/A | |
| Camille MD | Amylyx Pharmaceuticals | 72 | |
Management Performance
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.17 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael LLM, Chief VP | ||
| Birgitte MD, Sr Affairs | ||
| Stina MD, Executive Oncology | ||
| Scott Holmes, Head Endocrinology | ||
| Timothy Lee, Director Relations | ||
| Nyssa Noyola, Vice Management | ||
| Jens Okkels, VP Devel | ||
| Flemming Jensen, Senior Vice President Product Supply | ||
| Scott Smith, CFO, Senior Vice President | ||
| Mads Bodenhoff, Senior Officer | ||
| Jan Mikkelsen, CEO and President Member of Executive Board and Executive Director | ||
| Joseph Kelly, Head Endocrinology | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, Principal Accounting Officer and VP of Fin. | ||
| Kennett Sprogoe, Executive Development |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 10.3 B | ||||
| Shares Outstanding | 60.09 M | ||||
| Shares Owned By Insiders | 0.78 % | ||||
| Shares Owned By Institutions | 99.22 % | ||||
| Number Of Shares Shorted | 3.63 M | ||||
| Price To Earning | (9.10) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Tools for Ascendis Stock
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |